Predictive values of the ultrasound parameters, CA-125 and risk of malignancy index in patients with ovarian cancer

Klinicka Onkologie

Volumn 24, Issue 6, 2011, Pages 435-442

  Antovska, Vesna S ^a   Bashevska, N ^a   Aleksioska, N ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

CA 125 protein; Ovarian neoplasms; Prognosis; Serum; Tumor markers; Ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ARTICLE; ASCITES; BENIGN TUMOR; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84455163295     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 2006; 10(1): 77-81.
2. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med 2005; 50(6): 426-438. (Pubitemid 40863959)
3. Timor-Tritsch IE, Peisner DB, Montegudo A. Vaginal sonographic puncture procedures. In: Timor-Tritsch IE, Rottern S (eds). Transvaginal Sonography. New York: Elsevier 1991.
4. Hurwitz A, Yagel S, Zion I et al. The management of persistent clear pelvic cysts diagnosed by ultrasonography. Obstet Gynecol 1988; 72 (3 Pt 1): 320-322.
5. Hill LM, Nyberg DA. Transvaginally guided procedures. In: Nyberg Da, Hill LM, Böhm-Velez M et al. (eds). Transvaginal Ultrasound. St Lous: Mosby Year Book 1992.
6. Kurjak A, Shalan H, Matijevic R et al. Stage I ovarian cancer by transvaginal color Doppler sonography: a report of 18 cases. Ultrasound Obstet Gynecol 1993; 3(3): 195-198.
7. Woolas R, Jacobs I, Davies A et al. What is the true incidence of primary fallopian tube carcinoma? Int J Gynecol Cancer 1994; 4(6): 384-388.
8. Bast RC Jr, Klugg TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309(15): 883-887. (Pubitemid 13014028)
9. Hawkins RE, Roberts K, Wittshaw E et al. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 1989; 60(4): 634-637. (Pubitemid 19251466)
10. Maggino T, Gadducci A, D'Addano V et al. Prospective multicentar study on CA125 in postmenopausal pelvic masses. Gynecol Oncol 1994; 54(2): 117-123. (Pubitemid 24256456)
11. Jacobs I, Oram D, Fairbanks J et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97(10): 922-929. (Pubitemid 20340625)
12. Obeidat BR, Amarin ZO, Latimer JA et al. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004; 85(3): 255-258. (Pubitemid 38622556)
13. Tingulstad NS, Hagen B, Skjeldstad FE et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103(8): 826-831. (Pubitemid 26291762)
14. Bailey J, Tailor A, Naik R et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 2006; 16 (Suppl 1): 30-34.
15. Daya S. Diagnostic test-predictive values. Evidence-based Obstet Gynec 2005; 7: 71-73.
16. Tsukishiro S, Suzumori N, Nishikawa H et al. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005; 96(2): 516-519. (Pubitemid 40127158)
17. Rzymski P, Opala T, Woźniak J et al. Assessment of soluble intracellular adhesion molecule-1 (sICAM-1) in women with benign ovarian tumors. Ginekol Pol 2004; 75(10): 785-792.
18. Sagiv R, Golan A, Glezerman M. Laparoscopic management of extremely large ovarian cysts. Obstet Gynecol 2005; 105(6): 1319-1322. (Pubitemid 40734263)
19. Geomini PM, Kluivers KB, Moret E et al. Evaluation of adnexal masses with three-dimensional ultrasonography. Obstet Gynecol 2006; 108(5): 1167-1175. (Pubitemid 44665412)
20. Ulusoy S, Akbayir O, Numanoglu C et al. The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet 2007; 96(3): 186-191. (Pubitemid 46281908)
21. Bailey J, Tailor A, Naik R et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 2006; 16 (Suppl 1): 30-34
22. Szpurek D, Moszynaski R, Smolen A et al. Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses. Int J Gynaecol Obstet 2005; 89(2): 108-113. (Pubitemid 40585608)
23. Roupa Z, Faros E, Raftopoulos V et al. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. In Vivo 2004; 18(6): 831-836. (Pubitemid 40089635)
24. Moolthiya W, Yuenyao P. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Asian Pac J Cancer Prev 2009; 10(5): 865-868.
25. van den Akker PA, Aalders AL, Snijders MP et al. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecol Oncol 2010; 116(3): 384-388.
26. Montagnana M, Danese E, Ruzzenente O et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49(3): 521-525.